Skin and Connective Tissue Diseases

445 trials 165 recruiting

Filter these 445 trials by phase, country and sponsor.

Open in Search →

Study on the prevention of atopic dermatitis symptoms in children with a high risk of the disease through the regular use of a moisturizing … Ended

2024-513289-21-00 Children with a high risk of developing atopic dermatit 5 2020-01-13
Randomized double blind double dummy control trial comparing the safety and efficacy of rituximab versus oral cyclophosphamide in severe for… Ended

2024-514885-38-00 severe forms of mucous membrane pemphigoid 5 2019-07-11
A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Respo… Ended

2023-505477-33-00 Psoriatic Arthritis 5 2019-06-18
EffisayilTM ON: A study to test long-term treatment with spesolimab in people with generalized pustular psoriasis who took part in a previou… Ended

2023-509216-28-00 Generalized Pustular Psoriasis 4 2019-05-27
Medical-scientific research into a new own skin graft product (EHSG-KF) Ended

2024-512190-27-00 Adults and children with full thickness skin defects 4 2019-05-13
A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Ended

2023-505478-14-00 Psoriatic Arthritis 5 2019-05-09
Phase II multicentric study: efficacy evaluation of neo-adjuvant treatment associated with maintenance therapy by anti-PD1 immunotherapy on … Ended

2024-513027-16-00 Resectable mucosal melanomas 4 2018-05-28
DupuytrEn Treatment EffeCtiveness Trial (DETECT) Ended

2024-515110-40-00 Dupuytren's contracture 5 2017-09-15
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD). Ended

2023-509425-53-00 Atopic Dermatitis 5 2015-11-09
Phase 2a study to assess the efficacy and safety of GIA632 in adult participants with moderate to severe atopic dermatitis Halted

2025-521503-43-00 Atopic dermatitis 4 2026-02-12
The effect of SYX-5219 on an immune response in the skin. Ended

2025-522217-27-00 Atopic dermatitis (AD) 3 2025-11-19
Phase 1 Study to Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Men Participants Ended

2025-521402-18-00 Desmoid tumor 3 2025-10-24
An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers… Ended

2025-522921-37-00 inteneded for treatment of - active rheumatoid arthriti 2 2025-10-22
Assessment of the safety and effects on the body of investigational products when used on psoriatic skin Ended

2025-522446-51-00 Plaque psoriasis 3 2025-10-17
A Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib Compared to Deucravacitinib in Participants With Moderate-… Ended

2024-512497-10-00 Moderate to Severe Plaque Psoriasis 5 2025-09-16
The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune D… Ended

2024-518797-13-00 systemic lupus erythematosus [SLE]/lupus nephritis [LN] 3 2025-07-10
clinical trial evaluating the efficacy of nintedanib with tocilizumab compared to standard treatment in patients with systemic sclerosis and… Ended

2024-517005-85-00 systemic sclerosis with interstitial lung disease (ILD) 5 2025-07-01
Phase 1 study with topical cream RLS-1496 in patients with plaque psoriasis or Eczema Ended

2025-520514-64-00 Atopic Dermatitis 1 2025-04-04
Open-label basket study for safety and pharmacokinetics evaluation of INF904 in subjects with CSU or HS Ended

2024-515615-22-00 Moderate to Severe Chronic Spontaneous Urticaria (CSU) 4 2025-04-02
Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients with… Ended

2024-514562-40-00 Hidradenitis suppurativa (HS) 4 2025-03-13
A Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa Ended

2024-515959-38-00 Hidradenitis Suppurativa 4 2025-03-06
Phase 2, randomized, double-blind, placebo-controlled study of IC0624 as first-line therapy in patients with active mild to moderate Hidrade… Ended

2024-518180-35-00 Hidradenitis Suppurativa 4 2025-03-03
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac… Ended

2023-508959-39-00 Moderate to Severe Plaque Psoriasis 5 2025-02-20
A Phase 2, Dose-Ranging Study of LY4100511 (DC-853) in Adult Participants with Moderate-to-Severe Plaque Psoriasis Ended

2024-512207-39-00 Plaque Psoriasis 4 2025-01-30